1. Infectious Pathogen Detection - Seegene

Figure & Table. Result
Bottom Marker
Sample ID
Internal Control
T. vaginalis
M. hominis
M. genitalium
C. trachomatis
N. gonorrhoeae
U. urealyticum/parvum
Unidentified
Top Marker
Internal Control
T. vaginalis
M. hominis
M. genitalium
C. trachomatis
N. gonorrhoeae
U. urealyticum/parvum
Top Marker
Internal Control
C. glabrata
C. tropicalis
C. parapsilosis
C. krusei
C. albicans
C. dubliniensis
Bottom Marker
Bottom Marker
Sample ID
Internal Control
CMV
T. pallidum
H. ducreyi
LGV
GBS
Unidentified
Bottom Marker
Top Marker
Internal Control
CMV
T. pallidum
H. ducreyi
LGV
GBS
Bottom Marker
STI Master Panel 1 STI Master Panel 2
L2 L3 L4 L5 L6 L7
1 2 3 4 5 6
1~6: Clinical samples, 7: Negative control (ScreenTape® System, Lab901 Limited)
STI Master Panel 3
Bottom Marker L2 L3 L4 L5 L6 L7
L8
Sample ID
1 2 3 4 5 6
7
Internal Control
101
101
101
101
101 101 105
C. glabrata
84
C. tropicalis
91
C. parapsilosis
87
C. krusei
104
C. albicans
105
C. dubliniensis
Unidentified
64
1~6: Clinical samples, 7: Negative control (ScreenTape® System, Lab901 Limited)
STI Master Panel 5
L2 L3 L4 L5 L6 L7
1 2 3 4 5 6
101
102
101
102
100
102
62
101
53
100
62
86
101
102
76
1~6: Clinical samples, 7: Negative control (ScreenTape® System, Lab901 Limited)
100
102
101
59
53
Clinical
samples
1
2
3
4
5
6
101
102
100
61
101
82
100
101
Panel 3
Result
C. tropicalis
C. glabrata
L8
7
L8
7
C. parapsilosis
C. albicans
C. krusei
C. dubliniensis
101
100
Clinical Clinical
samples samples
1
2
3
4
5
6
Bottom Marker
Sample ID
Internal Control
G. vaginalis
B. fragilis
M. curtisii
A. vaginae
M. mulieris
Unidentified
Top Marker
Internal Control
G. vaginalis
B. fragilis
M. curtisii
A. vaginae
M. mulieris
Bottom Marker
Bottom Marker
Sample ID
Internal Control
T. vaginalis
HSV2
HSV1
Unidentified
Top Marker
Internal Control
T. vaginalis
HSV2
HSV1
Bottom Marker
Result Result
T. vaginalis
N. gonorrhoeae
M. hominis, C. trachomatis
STI Master Panel 4
M. genitalium, U. urealyticum/parvum
M. hominis
L2 L3 L4 L5 L6 L7
1 2 3 4 5 6
100
101
102
81
1~6: Clinical samples, 7: Negative control (ScreenTape® System, Lab901 Limited)
L2 L3 L4 L5 L6 L7
1 2 3 4 5 6
102
104
U. urealyticum/parvum
100
101
97
101
89
101
103
101
102
118
119
101
103
1~6: Clinical samples, 7: Negative control (ScreenTape® System, Lab901 Limited)
Figure & Table. Amplified PCR products using Seeplex® STI Master ACE Detection and result
analysis (Rapid & easy interpretation using ScreenTape® System).
1
2
3
4
5
6
Panel 1
Panel 4
T. vaginalis
HSV1
HSV2
T. vaginalis
T. vaginalis
HSV2
101
102
Clinical Clinical
samples samples
1
2
3
4
5
6
103
103
89
42
Clinical
samples
1
2
3
4
5
6
100
101
101
58
100
102
Result
L8
7
L8
7
101
100
G. vaginalis, B. fragilis, A. vaginae
G. vaginalis, A. vaginae
B. fragilis
M. curtisii
G. vaginalis, A. vaginae, M. mulieris
G. vaginalis, A. vaginae, M. mulieris
Result
T. pallidum
LGV, GBS
CMV, GBS
CMV
H. ducreyi
GBS
Panel 2
Panel 5
18

1.9 Diarrhea Detection
1.9.1 Diarrhea ACE Detection
Seeplex® Diarrhea ACE Detection detects diarrhea-causing viruses and/or bacteria directly from stool.
Current diagnostic methods for diarrhea such as electron microscopy, ELISA or stool culture contain certain limitations. With multiplex
PCR system based on DPO TM technology, the Seeplex® Diarrhea ACE Detection can detect 4 viruses and/or 10 bacteria causing diarrhea
within 6 hours.
Virus panel Bacteria panel
[4 RNA Viruses] [Panel B1] [Panel B2]
Rotavirus
Norovirus G I
Norovirus G II
Enteric adenovirus
Astrovirus
Detectable Pathogens for Diarrhea
1 Rotavirus, Norovirus GII 5
2 Norovirus GII
6
3
Norovirus GII
7
4
Norovirus GII
Salmonella spp.
Shigella spp.
Campylobacter spp.
Vibrio spp.
Clostridium difficile Toxin B
Fig. 1 & Table 1. Example Fig. 2 & Table 2. Example
Lane
Sample ID
Internal control
Astrovirus
Rotavirus
Adenovirus
Norovirus GI
Norovirus GII
Unidentified
Top Marker
Internal control
Astrovirus
Rotavirus
Adenovirus
Norovirus GI
Norovirus GII
Bottom Marker
Clinical
samples
Fig. 1 & Table 1. Amplified PCR products using Seeplex® Diarrhea -V
ACE Detection (Fig. 1) and result analysis (Table1).
Clostridium perfringens
Yersinia enterocolitica
Aeromonas spp.
E. coli O157:H7
Verocytotoxin-producing
E. coli (VTEC)
Seeplex®
Diarrhea ACE Detection
Product Cat. No. Size
Diarrhea-V ACE Detection DR6411Y 50 rxns
Diarrhea-B1 ACE Detection DR6501Y 50 rxns
Diarrhea-B2 ACE Detection DR6502Y 50 rxns
Seeplex® Diarrhea-V ACE Detection Seeplex® Diarrhea-B1 ACE Detection
L2
1
102
103
L3 L4 L5 L6 L7 L8
2
3
103 102 102
93 44 100 88 98
4
1~7: Clinical samples (ScreenTape® System, Lab901 Limited)
5
106
6
101 98
99
Rotavirus, Norovirus GII
Norovirus GI
Enteric adenovirus
7
99
100
Lane
Sample ID
Internal control
Vibrio spp.
C.difficile Toxin B
Salmonella spp.
Shigella spp.
Campylobacter spp.
Unidentified
Top Marker
Internal control
Vibrio spp.
C.difficile Toxin B
Salmonella spp.
Shigella spp.
Campylobacter spp.
Bottom Marker
Clinical
Result samples Result Clinical
samples
1
2
3
4
L2
L3 L4 L5 L6 L7 L8
1 2 3 4 5 6 7
101 101
105
99 101 97 98 101
99
101
81
100
98
80
1~7: Clinical samples (ScreenTape® System, Lab901 Limited)
Salmonella spp.
Vibrio spp.
Shigella spp.
Campylobacter spp.
Available specimen
Stool
Compatible instruments
ScreenTape® System (Lab901),
MCE-202, “MultiNA” (Shimadzu)
Clinical
Result samples Result
Fig. 2 & Table 2. Amplified PCR products using Seeplex® Diarrhea
-B1 ACE Detection (Fig. 2) and result analysis (Table2).
5
6
7
Salmonella spp., Shigella spp.
* _
C. difficile Toxin B
*Not detected.
30

Internal control
(360bp) van A
(250bp) van B
2.1 VRE ACE Detection
Seeplex® VRE ACE Detection detects the vanA and vanB genes which cause vancomycin-resistance in Enterococci
cultured in Enterococcosel broth/agar.
Enterococci are normally indigenous bacteria found in the GI tract and female genitals, but recently they were recognized as major
pathogens causing urinary tract infections and sepsis by nosocomial infection. Vancomycin, which is used in the treatment of enterococci
infection, is a drug that has an antibacterial effect by forming a complex with the D-alanyl-D-alanine terminal of the peptidoglycan precursor
to block transglycosylation and transpeptidation during the synthesis of the cell wall of Gram-positive cocci. However, vancomycinresistant
enterococci (VRE) tend to multiply rapidly due to the high frequency and continuous use of vancomycin.
Seeplex® VRE ACE Detection is a PCR method that incorporates DPO TM technology with high sensitivity and specificity, and is a product
that can test for the vancomycin-resistant vanA gene and the vanB gene of enterococci in one test.
Fig 1. Band information
M 1 2 3 N P S
Fig. 2 & Table 1. Example
M
M 1 2 3 N P S
M: VRE size marker | 1: vanA positive sample |
2: vanB positive sample | 3: Negative sample |
N: Negative control | P : Positive control |
S: 100 bp ladder
vanA
P
vanB
P
van A-positive control
(1010bp)
van B-positive control
(750bp)
Internal control
(520bp)
N 1 2 3 4 5 6 7 8 9 10 11 M
M: VRE size marker | P: Positive control | 1-11: Stool samples cultured in enterococcosel
broth | N: Negative control
Clinical
Sample
Result
Clinical
Sample
Result
1
*_
7
vanA
2
vanA
8
vanA
3
vanA
9
vanA
4
*_
10
vanA
5
vanA
11
*_
6
vanA
*Not detected.
Fig. 2 & Table 1. Amplified PCR products using Seeplex® VRE ACE Detection
were run on agarose gel and vanA gene was detected in 8 of 11 patient
samples.
2. Drug Resistance Detection
Available specimen
Enterococci cultured
in Enterococcosel broth/agar
Compatible instruments
ScreenTape® System (Lab901),
MCE-202, “MultiNA” (Shimadzu)
Internal
control
van A
van B
Fig. 3 & Table 2. Example
Top Marker
VanA-positive control
VanB-positive control
Internal Control
Clinical
Sample
1
2
3
4
VanA
VanB
Bottom Marker
®
VRE ACE Detection
Product Cat. No. Size
Seeplex® VRE ACE Detection VR1210Y 50 rxns
1 2 3 4 5 6 7
1~7: Stool samples cultured in enterococcosel broth (ScreenTape® System,
Lab901 Limited)
Result
vanA vanA
vanB
*- *-
*-
Clinical
Sample
5
6
7
Result
vanA
*Not detected.
Fig. 3 & Table 2. Amplicied PCR products using Seeplex® VRE
ACE Detection and result analysis. In this example, vanA
and vanB genes were successfully detected in 4 patient
samples. (Rapid & easy interpretation using ScreenTape®
System)
32

Seegene , Inc . (headquarters)
Seegene, Inc.
Taewon Bldg., 65-5, Bangyi-Dong,
Songpa-Gu, Seoul 138-050, Korea 138-050
Tel: +82-2-2240-4008, Fax: +82-2-2240-4040
E-mail : world@seegene.com
www.seegene.com
Seegene USA
9700 Great Seneca Highway, Rockville,
MD 20850, U.S.A.
Tel: +1-301-762-9066, +1-866-733-4949 (Toll free)
Fax: +1-301-762-9088, +1-866-733-4955 (Toll free)
E-mail : usa@seegene.com
www.seegene.com
Oct 2009 Eng v. 2.0